A multiorgan donor cancer screening protocol: The Italian Emilia-Romagna region experience

被引:25
作者
Fiorentino, M
D'Errico, A
Corti, B
Casanova, S
Ridolfi, L
Venturoli, N
Sestigiani, E
Grigioni, WF
机构
[1] Ist Oncol Addarii, Pathol Unit, I-40138 Bologna, Italy
[2] Univ Bologna, Sch Med, S Orsola M Malpighi Hosp, Ctr Riferimento Trapianti Reg Emilia Romagna, I-40126 Bologna, Italy
关键词
D O I
10.1097/01.TP.0000092306.29395.96
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. We describe the Emilia-Romagna screening protocol for all multiorgan donors within this region of Italy and report on the first 2 years of implementation. Setting. Setting is a 24-hour multidisciplinary call service covering the 16 intensive care units in Emilia-Romagna (3,969,000 inhabitants) and a centralised pathology center, directed by a transplant coordination center. Study Population and Period. All 271 effective donor candidates presenting in Emilia-Romagna in 2001-2002. Protocol. Anamnesis, external examination, and thorough laboratory and instrumental screening is followed by sampling of internal effusions and evaluation of all internal organs. All suspect findings are then investigated by extemporary pathologic evaluation. To fit national legal requirements, candidates are classified as standard risk (no transmissible risk); nonstandard risk (low-risk of transmission, eligibility restricted to certified clinical emergencies pending informed consent); and unacceptable risk (unconditional exclusion because of high-risk pathologies). Results. The protocol was successfully implemented for all 271 candidates. In addition to 14 independent exclusions, clinical suspicion of cancer was raised for 61 donors presenting with 82 lesions or effusions. Along with one case of lymph-node tuberculosis (unacceptable risk), histocytologic screening revealed eight cases of malignancy (5 prostate, 1 papillary-thyroid, 1 follicular-thyroid, and 1 renal cell, all nonstandard risk); the remainder were benign (standard risk). Protocol implementation led to exclusion of 8 (3.0%) candidates (1 nonstandard risk transplantation was performed). Conclusions. This stringent protocol-now adopted with some modifications at a national level-provides an initial example of a feasible intervention aimed at maximising donation safety while rationalizing use of marginal donors.
引用
收藏
页码:1695 / 1699
页数:5
相关论文
共 19 条
[1]  
[Anonymous], 2000, World Health Organisation Classification of Tumours: Pathology and genetics of tumours of the nervous system
[2]   Fate of a renal tubulopapillary adenoma transmitted by an organ donor [J].
Barrou, B ;
Bitker, MO ;
Delcourt, A ;
Ourahma, S ;
Richard, F .
TRANSPLANTATION, 2001, 72 (03) :540-542
[3]   Risk for tumor and other disease transmission by transplantation: A population-based study of unrecognized malignancies and other diseases in organ donors [J].
Birkeland, SA ;
Storm, HH .
TRANSPLANTATION, 2002, 74 (10) :1409-1413
[4]  
CONLON PJ, 1995, J AM SOC NEPHROL, V6, P54
[5]  
*COUNC EUR, 1997, TRANSPLANT NEWS, V2
[6]   Donor-acquired small cell lung cancer following pulmonary transplantation [J].
De Soyza, AG ;
Dark, JH ;
Parums, DV ;
Curtis, A ;
Corris, PA .
CHEST, 2001, 120 (03) :1030-1031
[7]  
Detry O, 1998, CLIN TRANSPLANT, V12, P579
[8]   Organ donors with positive viral serology or malignancy: Risk of disease transmission by transplantation [J].
Feng, S ;
Buell, JF ;
Cherikh, WS ;
Deng, MC ;
Hanto, DW ;
Kauffman, HM ;
Leichtman, AB ;
Lorber, MI ;
Maters, RG ;
McBride, MA ;
Metzger, RA ;
Nolte, FS ;
O'Connor, KJ ;
Roth, D ;
Terrault, NA ;
Henry, ML .
TRANSPLANTATION, 2002, 74 (12) :1657-1663
[9]  
*I SUP SAN CTR NAZ, 2002, ATT DON PREL TRAP IT, V2
[10]   Liver graft-transmitted glioblastoma multiforme. A case report and experience with 13 multiorgan donors suffering from primary cerebral neoplasia [J].
Jonas, S ;
Bechstein, WO ;
Lemmens, HP ;
Neuhaus, R ;
Thalmann, U ;
Neuhaus, P .
TRANSPLANT INTERNATIONAL, 1996, 9 (04) :426-429